Why the study?
What are the pharmacokinetic considerations of different treprostinil formulations and routes of administration in healthy volunteers and patients with PAH?
What are the pharmacokinetic considerations of different treprostinil formulations and routes of administration in healthy volunteers and patients with PAH?
This review provides a comprehensive overview of the pharmacokinetics of treprostinil across its four routes of administration to guide clinical decision-making in pulmonary arterial hypertension.
May inform treprostinil formulation and route selection in PAH; extends PK data synthesis but leaves prospective outcome validation open.
Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso® (treprostinil sodium, inhaled administration), and Orenitram® (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). Pharmacokinetic studies have been performed in healthy volunteers and patients with PAH. The intent of this review is to outline pharmacokinetic considerations of the three treprostinil formulations and provide clinicians with a resource that may support clinical decisions in treating patients with PAH.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: